This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
Kidney Cancer
RadiCal
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
FORT
NRG-GU 0101
Oral EPI-7386
RTIRE
SHORTER
SPLASH
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Translational Prostate Cancer
Andrea Miyahira, Ph.D
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
EnDOUROLOGY
Sumanta (Monty) Kumar Pal, MD||Jaime Landman, MD
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Health Policy
Ruchika Talwar, MD
WOMEN IN SCIENCE
Andrea Miyahira, Ph.D
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Suprapubic Catheter
Diane K. Newman, DNP FAAN BCB-PMD
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Pelvic
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASTRO 2023
SNMMI 2023
ProsTIC/PCF Global Webinar 2023
ASCO 2023
AUA 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2021
ASCO GU 2021
Prostate Cancer
Bladder Cancer
Kidney Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
ASCO GU 2021 Bladder Cancer
Viewing 21-40 of 50 articles
ASCO GU 2021: Heterogeneity in Nectin-4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
ASCO GU 2021: Phase II/III Clinical Results of IL-15RαFc Superagonist N-803 With BCG in BCG-Unresponsive NMIBC Carcinoma In Situ Patients
ASCO GU 2021: Characterization of FOXF1 as a Novel Regulator of Nodal Metastasis in Bladder Cancer
ASCO GU 2021: Avelumab First-Line Maintenance Plus Best Supportive Care vs Best Supportive Care Alone For Advanced Urothelial Carcinoma: JAVELIN Bladder 100 Subgroup Analysis Based On Duration And Cycles Of First-Line Chemotherapy
ASCO GU 2021: Association Between Tumor Mutational Burden and Immune-Related Adverse Events in Patients with Metastatic Urothelial Carcinoma During Checkpoint Immunotherapy
ASCO GU 2021: Cost-Effectiveness Analysis of Pembrolizumab for BCG-Unresponsive Carcinoma in Situ of the Bladder
ASCO GU 2021: Invited Discussion: Enfortumab Vedotin in Previously Treated Urothelial Cancer
ASCO GU 2021: Pembrolizumab for the Treatment of Patients with High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin: Extended Follow-up of KEYNOTE-057 Cohort A
ASCO GU 2021: SURE: An Open Label, Sequential-Arm, Phase II Study of Neoadjuvant Sacituzumab Govitecan, and Sacituzumab Govitecan plus Pembro Before Radical Cystectomy, for Patients with MIBC Who Cannot Receive or Refuse Cisplatin-Based Chemotherapy
ASCO GU 2021: Updated Outcomes of POUT: A Phase III Randomized Trial of Peri-Operative Chemotherapy Versus Surveillance in Upper Tract Urothelial Cancer
ASCO GU 2021: Alignment and Discordances in Perceptions and Experiences of Shared Decision Making Among Bladder Cancer Patients and Their Care Team
ASCO GU 2021: EV-201 Cohort 2: Enfortumab Vedotin In Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer Who Received Prior PD-1/PD-L1 Inhibitors
ASCO GU 2021: Optimal Therapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer in the Non-cystectomy Candidate - Systemic
ASCO GU 2021: Safety and Efficacy Of Perioperative Cisplatin/Gemcitabine And Durvalumab For Operable Muscle-Invasive Urothelial Carcinoma: SAKK 06/17
ASCO GU 2021: Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
ASCO GU 2021: Atezolizumab Monotherapy vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Outcomes by PD-L1 Status In Cisplatin-Ineligible Patients From the Phase III IMvigor130 Study
ASCO GU 2021: Optimal Therapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer in the Non-cystectomy Candidate - Intravesical
ASCO GU 2021: Approaches to Immune Checkpoint Inhibitor Maintenance Therapy in Metastatic Urothelial Cancer: A Qualitative Analysis of Oncology Providers in the United States
ASCO GU 2021: Best of Journals: Urothelial Cancer - Surgery
ASCO GU 2021: Best of Journals: Urothelial Cancer - Radiation Oncology
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free